MétaCan
Menu
Back to cohort
Record W1033994473

The antidepressant debate and ethically defensible placebo-controlled trials.

2009· article· en· W1033994473 on OpenAlexaff
Duff R. Waring

Bibliographic record

VenuePubMed · 2009
Typearticle
Languageen
FieldNeuroscience
TopicPain Management and Placebo Effect
Canadian institutionsYork University
Fundersnot available
KeywordsPlaceboClinical trialClinical equipoiseAntidepressantIntervention (counseling)MedicineRandomized controlled trialPsychiatryPsychologyPsychotherapistAlternative medicineIntensive care medicineInternal medicine
DOInot available

Abstract

fetched live from OpenAlex

A basic tenet of biological psychiatry is that place bo-controlled, randomized drug trials under double blind have shown that antidepressants exert pharmacological efficacy-in other words, that they induce specific and measurable drug effects on research subjects. But there is ongoing dissention about whether pharmacological efficacy has been established reliably by these trials. The antidepressant debate indicates a split in the expert clinical community about the size of the drug/placebo difference and whether the mechanisms that produce it stem from the subjects' expectation of benefit or from the intervention's pharmacological prop erties. A basic tenet of research ethics is that if standard effective treatments exist, then clinical equipoise requires their use as active controls against which novel, nonvali dated treatments are tested. Substituting a placebo for an effective treatment in the control arm of a trial does not maintain this duty, as it exposes research subjects to an intervention that is known to be inferior. Defenders of clinical equipoise argue that conducting a trial is not an invitation to practice substandard medicine.' They have also argued that legal liability concerns might be raised about placebo-controlled trials of antidepressants.2 These ethical and legal concerns can be assessed with reference to cases in which clinical equipoise permits placebo-controlled trials. Given the recurring questions about whether the drug/placebo difference results from specific biological effects of antidepressants or from fac tors introduced by placebo response that have not been adequately excluded, I think a plausible argument can be made that clinical equipoise would permit the use of active placebo controls in the clinical trials that test them. This argument can be abbreviated to three premises and a conclusion. The first premise is that placebo con trols for drug trials are ethically defensible and scientifi cally justified when we have evidence leading to a rea sonable concern that a standard treatment might only work because of expectancy enhanced by side effects i.e., by enhanced placebo effects. The second premise is that this evidence must be endorsed by at least a respectable minority of the expert clinical community. Premise three asserts that a respectable minority of the expert clinical community endorses evidence leading to a reasonable concern that standard antidepressants might only work by enhanced placebo effects. If these premises are sound, then one can conclude that placebo controls for antidepressant trials are ethically defensible and sci entifically justified.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.318
metaresearch head score (Gemma)0.392
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Theoretical or conceptual · Consensus signal: Theoretical or conceptual
GenreCandidate signal: Commentary · Consensus signal: Commentary
Teacher disagreement score0.318
Threshold uncertainty score0.841

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.3180.392
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0030.002
Bibliometrics0.0020.002
Science and technology studies0.0040.046
Scholarly communication0.0080.015
Open science0.0040.005
Research integrity0.0410.037
Insufficient payload (model declined to judge)0.0050.002

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.055
GPT teacher head0.277
Teacher spread0.221 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

Study designTheoretical or conceptual
Domainnot available
GenreCommentary

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2009
Admission routes1
Has abstractyes

Explore more

Same venuePubMedSame topicPain Management and Placebo EffectFrench-language works237,207